Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT04699305
Recruiting Observational

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

NCT04699305 · tracked via the Priya Life Science USA tracker
Sponsor
RedDress Ltd
Phase
Observational
Started
2019-02-14
Last updated
2025-07-29

Condition(s) studied

Cutaneous Wounds

Investigational drug(s) / intervention(s)

ActiGraft

ActiGraft: Whole blood clot (WBC) gel

Study summary

Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject is ≥18 years of age * Subject has an exuding cutaneous wound * Subject agrees to the use of his health data, including photos of his wound in analysis and publications * Subject/LAR must be able to read and understand English and/or Spanish Exclusion Criteria: * Subject/LAR is unable to read and understand English or Spanish.

Primary outcome measure(s)

  • Percentage area reduction (PAR) at 4 weeks — 4 weeks
    Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).
  • Nature, frequency, and severity of adverse events in the intent to treat population — 1 year
    Nature, frequency, and severity (by CTCAE5) of adverse events

Trial sites (1)

FacilityCityRegionStatus
Wound Care Experts Las Vegas Nevada Recruiting

More RedDress Ltd. trials in the USA

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04699305 on ClinicalTrials.gov ↗ ← All trials in the USA